Retracted coronavirus (COVID-19) papers – Retraction Watch
Elsevier: Preprints With The Lancet Launches on SSRN
For Authors: Submit your work
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
How swamped preprint servers are blocking bad coronavirus research
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system - The Lancet Infectious Diseases
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - The Lancet
An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study - The Lancet
Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever | Nature Medicine
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study - eBioMedicine
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis - The Lancet Microbe
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial - The Lancet
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility - The Lancet Global Health
The Lancet, 14 October 2023, Volume 402, Issue 10410, Pages 1299-1392
Flawed preprint based on autopsies inadequate to demonstrate that COVID-19 vaccines caused 74% of those deaths - Health Feedback
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
